Background: Airspace dimension assessment with nanoparticles (AiDA) is a novel method to measure distal airway morphology non-invasively. In this study, AiDA-derived airspace radii were measured in an unselected, cross-sectional study population. Persons with emphysema detected by computed tomography (CT) were compared to non-emphysematous subjects. Method: Nanoparticle inhalation tests, from which distal airspace radius (rAiDA) were calculated, were conducted on 618 individuals aged 50-64 years participating in the population-based Swedish CArdiopulmonary BioImaging Study (SCAPIS). The radius was studied in relation to visual and densitometric assessment of emphysema, as well as to lung function tests and symptoms. Findings: The forty-seven individuals with visually detected emphysema had a significantly larger rAiDA (326 ± 49 µm), compared to non-emphysematous persons (291 ± 36 µm), p = 0.00001. Odds ratio per 1 µm for emphysema, adjusted for age, sex, height and weight was 1·021 (1·013 - 1·028), p<0·0001. Similar results were found when other lung function measures were assessed. Interpretation: AiDA can indicate distal airspace enlargement and is a potential biomarker for emphysema. A diagnostic accuracy study in patients with suspected lung disease is needed to establish AiDA as a diagnostic technique. Funding: The study has received support from the Swedish Heart and Lung Foundation, The Swedish Research Council, FORTE, the Crafoord foundation, the Swedish Governmental Agency for Innovation Systems, the ERA-NET project EuroNanoMed2, and governmental funding of clinical research within the National Health Services. Declaration of Interest: The funders of the study had no commercial interests. Ethical Approval: The study was approved by the Regional Ethical Review Board in Umea, Sweden, 2010/228-31, and performed according to the Declaration of Helsinki.
Read full abstract